3.02
price up icon2.37%   0.07
after-market Handel nachbörslich: 3.02
loading
Schlusskurs vom Vortag:
$2.95
Offen:
$2.93
24-Stunden-Volumen:
623.01K
Relative Volume:
0.39
Marktkapitalisierung:
$214.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.9152
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-0.33%
1M Leistung:
+33.63%
6M Leistung:
+39.81%
1J Leistung:
+7.86%
1-Tages-Spanne:
Value
$2.881
$3.05
1-Wochen-Bereich:
Value
$2.881
$3.3499
52-Wochen-Spanne:
Value
$0.783
$3.39

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Firmenname
Ventyx Biosciences Inc
Name
Telefon
(858) 945-2393
Name
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Mitarbeiter
79
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
VTYX's Discussions on Twitter

Vergleichen Sie VTYX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VTYX
Ventyx Biosciences Inc
3.02 215.62M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-12 Hochstufung Oppenheimer Perform → Outperform
2024-03-12 Hochstufung Wells Fargo Equal Weight → Overweight
2023-11-07 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-11-07 Herabstufung Oppenheimer Outperform → Perform
2023-11-07 Herabstufung Stifel Buy → Hold
2023-11-07 Herabstufung Wells Fargo Overweight → Equal Weight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-03-21 Eingeleitet Wells Fargo Overweight
2022-12-19 Eingeleitet Goldman Buy
2022-11-17 Eingeleitet Morgan Stanley Overweight
2022-09-07 Eingeleitet Stifel Buy
2022-09-01 Eingeleitet H.C. Wainwright Buy
2022-05-09 Eingeleitet Credit Suisse Outperform
2022-03-31 Eingeleitet Canaccord Genuity Buy
2022-02-01 Eingeleitet Oppenheimer Outperform
2021-11-15 Eingeleitet Jefferies Buy
2021-11-15 Eingeleitet Piper Sandler Overweight
Alle ansehen

Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Ventyx Biosciences Inc. stockAccelerated earnings growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ventyx Biosciences Inc. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ventyx Biosciences Inc. a good long term investmentTremendous return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 16, 2025

What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com

Jul 10, 2025
pulisher
Jul 03, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire

Jul 03, 2025
pulisher
Jun 30, 2025

Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World

Jun 27, 2025
pulisher
Jun 23, 2025

Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com

Jun 23, 2025
pulisher
Jun 18, 2025

Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest

Jun 18, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 15, 2025

Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria

Jun 15, 2025
pulisher
Jun 12, 2025

Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 10, 2025

Ventyx Biosciences reports annual meeting results - Investing.com

Jun 10, 2025

Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):